Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Tetraphase Pharmaceu (TTPH)

Tetraphase Pharmaceu (TTPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc. Globe NewsWire - Tue Jul 28, 2020

-Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases-

LJPC : 6.22 (unch)
TTPH : 2.20 (-3.51%)
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc. Globe NewsWire - Wed Jun 24, 2020

La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights

LJPC : 6.22 (unch)
TTPH : 2.20 (-3.51%)
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc. Business Wire - Wed Jun 24, 2020

La Jolla Pharmaceutical Company, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta Business Wire - Mon Jun 22, 2020

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)
Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals Business Wire - Thu Jun 4, 2020

Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ to treat serious and life-threatening infections, today announced...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx Business Wire - Mon Jun 1, 2020

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration Business Wire - Fri May 29, 2020

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx Business Wire - Wed May 27, 2020

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration Business Wire - Wed May 27, 2020

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA ™ (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Determination of Superior Offer and Notice to AcelRx Business Wire - Thu May 21, 2020

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xerava™ (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)

Barchart Exclusives

3 Dividend Aristocrats to Buy on Every Dip Barchart - Wed Apr 24, 6:30PM CDT
As markets get wobbly, here are three Dividend Aristocrats to add a little stability to any portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot